Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documental congenital FXIII deficiency~* Normal platelet count and clotting parameters~* Adequate renal and hepatic function~* If female and of child-bearing potential, negative serum pregnancy test within 7 days of enrollment~* If a sexually active male or a sexually active female of child-bearing potential, agreement to use a medically accepted form of contraception from the time of enrollment to completion of all follow-up study visits~* Negative drug and alcohol screens~Exclusion Criteria:~* Received blood products or FXIII concentrates within 4 weeks of study enrollment~* Known antibodies to FXIII~* Hereditary or acquired coagulation disorder other than FXIII deficiency~* Previous history of autoimmune disorders involving autoantibodies e.g., systemic lupus erythematosus~* Previous history of thromboembolic events e.g., cerebrovascular accident or deep vein thrombosis or administration of any antithrombotic or antiplatelet drugs within 7 days of study enrollment~* Received treatment with any experimental agent within 30 days of study enrollment~* Any surgical procedure in the 30 days prior to enrollment~* Donated blood within 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rFXIII (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).